ArticleCell communication and signaling : CCS2026
The role of KDM5B in creating synthetic vulnerabilities in combination with radiotherapy in melanoma cells.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous melanoma is the most aggressive type of skin cancer, with survival rates declining due to tumor heterogeneity and therapy resistance. Distinct subpopulations, including slow-cycling, therapy-resistant cells with high expression of the histone demethylase KDM5B, contribute to tumor progression and poor outcomes. Intermittent cycling hypoxia, defined by repeated hypoxia followed by reoxygenation, promotes tumor plasticity and aggressiveness, yet its role in melanoma heterogeneity and resistance remains poorly understood.
methodsWe established hypoxia/reoxygenation-tolerant (HRT) melanoma cell lines (Hx10) through 10 cycles of intermittent cycling hypoxia (48 h at 0.2% O₂ followed by 120 h at 20.9% O₂) under conditions of KDM5B overexpression. Radiation response was evaluated in Hx10 and nonselected control cells. To investigate adaptive mechanisms, we performed reversed-phase protein array (RPPA) screening and applied an information-theoretic approach to compute protein-specific altered signaling signatures. Pathway enrichment analyses were used to identify dysregulated subnetworks.
resultsHx10 melanoma cells displayed increased resistance to radiation compared with nonselected control cells. Proteomic profiling identified distinct signaling signatures associated with KDM5B overexpression and adaptation to cycling hypoxia. These signatures revealed coexpressed subnetworks involving DNA repair, PI3K/AKT/mTOR, AMPK, and autophagy pathways, several of which are implicated in therapy resistance. Functional assays demonstrated that targeting either KDM5B or PI3K reduced the radioresistance of Hx10 melanoma cells. Sequential combination treatments impaired repopulation ability, particularly when KDM5B overexpression was withdrawn, indicating dependence on KDM5B for survival.
conclusionsOur findings provide proof-of-concept that altered signaling signatures can be used to define novel vulnerabilities in melanoma. KDM5B overexpression promotes adaptation to intermittent cycling hypoxia and confers resistance to radiation through activation of DNA repair and survival pathways. Targeting KDM5B or PI3K in combination with radiotherapy may represent a promising strategy to overcome resistance and improve treatment outcomes in melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.